PTC Therapeutics Earnings Estimate

PTCT Stock  USD 69.45  1.25  1.77%   
The next projected EPS of PTC Therapeutics is estimated to be -0.2175 with future projections ranging from a low of -0.87 to a high of 0.2375. PTC Therapeutics' most recent 12-month trailing earnings per share (EPS TTM) is at 8.6. Please be aware that the consensus of earnings estimates for PTC Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Yuan Drop
 
Covid
 
Interest Hikes
PTC Therapeutics is projected to generate -0.2175 in earnings per share on the 31st of December 2026. PTC Therapeutics earnings estimates show analyst consensus about projected PTC Therapeutics EPS (Earning Per Share). It derives the highest and the lowest estimates based on PTC Therapeutics' historical volatility. Many public companies, such as PTC Therapeutics, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm.

PTC Therapeutics Revenue Breakdown by Earning Segment

By analyzing PTC Therapeutics' earnings estimates, investors can diagnose different trends across PTC Therapeutics' analyst sentiment over time as well as compare current estimates against different timeframes. At this time, PTC Therapeutics' Gross Profit is comparatively stable compared to the past year. Gross Profit Margin is likely to gain to 0.88 in 2026, whereas Pretax Profit Margin is likely to drop (0.43) in 2026. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PTC Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in services.
For more information on how to buy PTC Stock please use our How to Invest in PTC Therapeutics guide.

PTC Therapeutics Earnings Estimation Breakdown

The calculation of PTC Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of PTC Therapeutics is estimated to be -0.2175 with the future projection ranging from a low of -0.87 to a high of 0.2375. Please be aware that this consensus of annual earnings estimates for PTC Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.
Last Reported EPS
0.0
-0.87
Lowest
Expected EPS
-0.2175
0.24
Highest

PTC Therapeutics Earnings Projection Consensus

Suppose the current estimates of PTC Therapeutics' value are higher than the current market price of the PTC Therapeutics stock. In this case, investors may conclude that PTC Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and PTC Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyLast Reported EPSEstimated EPS for 31st of December 2026Current EPS (TTM)
1561.87%
0.0
-0.2175
8.6

PTC Therapeutics Earnings per Share Projection vs Actual

Actual Earning per Share of PTC Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering PTC Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of PTC Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

PTC Therapeutics Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as PTC Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of PTC Therapeutics should always be considered in relation to other companies to make a more educated investment decision.

PTC Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact PTC Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
null
nullnullnullnull
null
nullnullnullnull
2025-11-04
2025-09-30-1.120.21.32117 
2025-08-07
2025-06-30-1.06-0.830.2321 
2025-04-23
2025-03-31-0.70510.0410.7451524 
2025-02-26
2024-12-31-0.65-0.34160.308447 
2024-11-07
2024-09-30-1.44-1.390.05
2024-08-08
2024-06-30-1.05-1.27-0.2220 
2024-04-25
2024-03-31-1.24-1.20.04
2024-02-29
2023-12-310.5-0.24-0.74148 
2023-10-26
2023-09-30-1.17-1.76-0.5950 
2023-08-03
2023-06-30-1.71-2.66-0.9555 
2023-04-27
2023-03-31-1.52-1.88-0.3623 
2023-02-21
2022-12-31-1.59-1.89-0.318 
2022-10-27
2022-09-30-1.24-1.53-0.2923 
2022-08-04
2022-06-30-1.33-2.13-0.860 
2022-05-03
2022-03-31-1.51-1.78-0.2717 
2022-02-22
2021-12-31-1.65-2.03-0.3823 
2021-10-28
2021-09-30-1.49-1.89-0.426 
2021-07-29
2021-06-30-1.82-1.680.14
2021-05-04
2021-03-31-1.51-1.83-0.3221 
2021-02-25
2020-12-31-0.94-1.08-0.1414 
2020-10-29
2020-09-30-0.06-1.03-0.971616 
2020-08-05
2020-06-30-1.3-2.62-1.32101 
2020-04-30
2020-03-31-1.33-1.81-0.4836 
2020-03-02
2019-12-31-0.51-1.37-0.86168 
2019-10-29
2019-09-30-0.76-1.06-0.339 
2019-08-06
2019-06-30-0.58-0.75-0.1729 
2019-05-02
2019-03-31-0.76-1.29-0.5369 
2019-02-28
2018-12-31-0.32-0.58-0.2681 
2018-11-05
2018-09-30-0.4-1.06-0.66165 
2018-08-07
2018-06-30-0.29-0.210.0827 
2018-05-09
2018-03-31-0.43-0.46-0.03
2018-03-06
2017-12-31-0.140.030.17121 
2017-11-02
2017-09-30-0.68-0.82-0.1420 
2017-08-08
2017-06-30-1.28-0.440.8465 
2017-05-08
2017-03-31-1.03-0.850.1817 
2017-03-16
2016-12-31-1.07-0.780.2927 
2016-11-02
2016-09-30-1.22-1.030.1915 
2016-08-04
2016-06-30-1.27-1.140.1310 
2016-05-05
2016-03-31-1.26-1.220.04
2016-02-29
2015-12-31-1.24-1.5-0.2620 
2015-11-09
2015-09-30-1.15-1.27-0.1210 
2015-07-30
2015-06-30-1.2-1.140.06
2015-05-04
2015-03-31-1.2-1.150.05
2015-02-27
2014-12-31-0.82-0.84-0.02
2014-11-06
2014-09-30-0.9-0.93-0.03
2014-08-07
2014-06-30-0.74-0.86-0.1216 
2014-05-06
2014-03-31-0.46-0.58-0.1226 
2014-03-06
2013-12-31-0.57-0.75-0.1831 
2013-11-14
2013-09-30-0.3-0.190.1136 
2013-08-12
2013-06-30-0.77-5.51-4.74615 

About PTC Therapeutics Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of PTC Therapeutics earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current PTC Therapeutics estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as PTC Therapeutics fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for Next Year
Retained Earnings-3.3 B-3.1 B
Retained Earnings Total Equity-2.4 B-2.3 B
Earnings Yield(0.12)(0.13)
Price Earnings Ratio(10.98)(11.53)
Price Earnings To Growth Ratio 0.25  0.27 

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for PTC Stock Analysis

When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.